Waldencast's asset-light, omnichannel model and early international expansion position it for strong premiumization, acquisition opportunities, and higher-than-expected long-term earnings growth. However, the company faces operational challenges, with H1 2025 net loss of $185.2M driven by goodwill impairments of $132.1M (Obagi) and $20.0M (Milk Makeup), and announced sale of Obagi Medical to Bridgepoint (June 1, 2026), representing a strategic restructuring.
Cyborg Score Rationale
Waldencast operates premium beauty brands with strong digital capabilities and international reach, but faces significant profitability challenges, recent goodwill impairments, and strategic divestitures. The sale of Obagi Medical signals a repositioning toward the higher-growth Milk Makeup segment.
Top Insights
Q2 2025 net revenue of $66.8M grew 5.6% YoY with Adjusted EBITDA margin of 5.0%
Q3 2025 net revenue declined 3.4% YoY to $67.8M; Obagi Medical grew double-digit while Milk Makeup declined
Cleared SEC probe over Obagi-related accounting issues (April 28, 2026)
FDA approval of Obagi Saypha MagIQ filler and acquisition of Novaestiq represent product innovation and M&A activity
Named Competitors
Estée Lauder Companies — Prestige skincare and cosmetics portfolio
Ulta Beauty — Premium beauty retail and brand distribution
Revlon — Color cosmetics and beauty products
The Ordinary / Deciem — Direct-to-consumer skincare innovation
Recent Developments
(June 2026) Announced sale of Obagi Medical segment to Bridgepoint, signaling major portfolio restructuring
(April 2026) Cleared SEC probe over Obagi-related accounting issues
(November 2025) Sold Obagi trademark rights in Japan to Rohto Pharmaceutical for $82.5M; refinanced credit facility with Lumina Capital
(November 2025) H1 2025 results showed $185.2M net loss driven by goodwill impairments
Open the full interactive Waldencast plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.